- ►nih.gov - Free from Publisher L Arias, O Pujol, J Berniell, M Rubio, G Roca, … - British Journal of Ophthalmology, 2005 - bjo.bmj.com Results: 64 patients (mean (SD) age, 76.7 (7.7) years; range 58–95 years) were
recruited to participate in the study. All participants in the study completed
the follow up time (mean 16.6 months). 24 patients (75%) in the group of ... Cited by 16 - Related articles - All 8 versions
S Sivaprasad, GM Saleh, H Jackson - Eye, 2005 - nature.com Photodynamic therapy (PDT) is a new evidence-based treatment modality available
for choroidal neovascularisation (CNV) secondary to age-related macular
degeneratin (AMD). Eligibility for PDT is based on the morphological ... Cited by 14 - Related articles - BL Direct - All 5 versions
S Michels, J Wachtlin, MA Gamulescu, H … - Ophthalmology, 2005 - Elsevier To compare the efficacy and safety of early retreatment with verteporfin therapy
with that of approved standard verteporfin therapy in neovascular age-related
macular degeneration. ... Two hundred three patients with predominantly ... Cited by 13 - Related articles - All 15 versions
BI Gaynes, RG Fiscella - eds, 2004 - Informa Pharma Science Photodynamic therapy (PDT) is a novel treatment entity that exploits the
photophysical properties of various photosensitive chemical entities which, upon
light activation, results in targeted photooxidation and subsequent tis- ... Cited by 5 - Related articles - BL Direct - All 5 versions
KKM FRANZCO, AR FRCOphth, JW BMBC, … - Clinical & Experimental Ophthalmology - interscience.wiley.com Methods: A retrospective review of 172 eyes of 172 consecutive patients who
received photodynamic therapy for predominantly classic with and without occult,
minimally classic and occult choroidal neovascular membranes secondary to ... Cited by 5 - Related articles - BL Direct - All 3 versions
- ►tau.ac.il [PDF] R Axer-Siegel, R Ehrlich, Y Yassur, I … - American journal of ophthalmology, 2004 - Elsevier Mean follow-up was 15.6 months. Patients received a mean of 3.4 treatments per
year. Sixty-six percent lost less than 3 Snellen lines of visual acuity. Three
patients (4%) experienced profound visual acuity loss to finger counting. ... Cited by 30 - Related articles - All 21 versions
- ►adisonline.com [PDF] J Wickens, KJ Blinder - Drug safety, 2006 - ingentaconnect.com The prevalence of neovascular age-related macular degeneration (AMD) is Abstract
expected to increase significantly during the next 20 years. New treatment
alternatives to laser photocoagulation are on the horizon – the first of ... Cited by 10 - Related articles - BL Direct - All 6 versions
SM Hariprasad, GK Shah - Ophthalmic surgery, lasers & imaging: the official … - ncbi.nlm.nih.gov To report the results of treating juxtafoveal choroidal neovascularization with
photodynamic therapy using verteporfin in eyes with age-related macular
degeneration. Seven patients with predominantly classic juxtafoveal ... Cited by 2 - Related articles - All 3 versions
- ►duanessolution.com F Parmeggiani, C Costagliola, D Gemmati, S D' … - Pharmacogenetics and Genomics, 2007 - journals.lww.com Page 1. Original article 1039 Predictive role of coagulation-balance gene polymorphisms
in the efficacy of photodynamic therapy with verteporfin ... Cited by 3 - Related articles - BL Direct - All 8 versions
F Parmeggiani, C Costagliola, C Incorvaia, … - Ophthalmology, 2006 - Elsevier In the course of our routine clinical practice, we have observed only one case
of ASVD after photodynamic therapy, with poor visual outcome. This adverse event
occurred in a 68-year-old white woman suffering from AMD and subfoveal ... Cited by 4 - Related articles - All 10 versions
